{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Tract&page=22", "query": { "condition": "Biliary Tract", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 719, "total_pages": 72, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Tract&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Tract&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T23:48:39.019Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02704364", "title": "A Study of NGM282 in Patients With Primary Sclerosing Cholangitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Sclerosing Cholangitis" ], "interventions": [ { "name": "NGM282", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 62, "start_date": "2016-03", "completion_date": "2017-06", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 26, "location_summary": "Sacramento, California • San Clemente, California • San Francisco, California + 21 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Clemente", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02704364" }, { "nct_id": "NCT02267707", "title": "Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasms", "Cholestasis" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-05-27", "completion_date": "2016-02-10", "has_results": false, "last_update_posted_date": "2019-11-01", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Detroit, Michigan", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02267707" }, { "nct_id": "NCT05482893", "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastroesophageal Junction Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)", "Colorectal Cancer" ], "interventions": [ { "name": "Spevatamig (PT886)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "CAPOX", "type": "DRUG" }, { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "TAS 102", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine Combined With Cisplatin", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2023-03-15", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05482893" }, { "nct_id": "NCT02197338", "title": "Randomized Trial of Wire and Sphincterotome Systems for Biliary Cannulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cholestasis, Extrahepatic" ], "interventions": [ { "name": "Bile Duct Cannulation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2016-04", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-04-15", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02197338" }, { "nct_id": "NCT01173159", "title": "Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cholestasis" ], "interventions": [ { "name": "Omegaven", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Month to 18 Years" }, "enrollment_count": 10, "start_date": "2010-07", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2020-06-17", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01173159" }, { "nct_id": "NCT04024813", "title": "A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Sclerosing Cholangitis" ], "interventions": [ { "name": "Seladelpar", "type": "DRUG" }, { "name": "Placebo to match Seladelpar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-11-12", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 8, "location_summary": "San Francisco, California • Aurora, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Novi", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04024813" }, { "nct_id": "NCT00789958", "title": "S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 105, "start_date": "2008-12", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2018-04-09", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 251, "location_summary": "Anniston, Alabama • Little Rock, Arkansas • Berkeley, California + 181 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00789958" }, { "nct_id": "NCT05775159", "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2023-04-24", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05775159" }, { "nct_id": "NCT02375880", "title": "Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma of Intrahepatic and Extra-hepatic Biliary System", "Carcinoma of Gallbladder", "Bile Duct Cancer", "Cholangiocarcinoma" ], "interventions": [ { "name": "DKN-01", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 51, "start_date": "2015-06", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 9, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02375880" }, { "nct_id": "NCT07146646", "title": "Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Tract Cancer", "Biliary Tract Neoplasms", "Cholangiocarcinoma", "Gallbladder Cancer", "Gallbladder Carcinoma" ], "interventions": [ { "name": "Trifluridine/tipiracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 27, "start_date": "2025-12-01", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-15T23:48:39.019Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07146646" } ] }